In March 2025, the company declared new options for the direct-to-purchaser offering of its Wegovy weight loss drug. The company proven a fresh pharmacy, called NovoCare, which would cost customers $499 monthly for use of the drug, below fifty percent the expense of the drug as a result of other pharmaceutical distribution networks.[fifty three]At